<DOC>
	<DOCNO>NCT02496988</DOCNO>
	<brief_summary>The purpose study determine whether combine Temozolomide cytokine-induced killer cell ( CIK ) transfusion prolong survival patient Advanced Malignant Gliomas . The effectiveness safety CIK cell treatment Malignant Glioma also evaluate .</brief_summary>
	<brief_title>Effect Cytokine-induced Killer Cells Advanced Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Subjects document histologically confirm primary grade 4 advance malignant glioma . No 3 prior relapse prior systemic treatment . Recurrent disease document MRI prior therapy . Must least one site bidimensionally measurable disease : archive tissue initial diagnosis advance malignant glioma upon transformation advance malignant glioma available central review within approximately 4 week enrollment . Completed least one full cycle temozolomide 200 mg/m2/day administer Days 15 28day cycle , without unacceptable toxicity progression . Karnofsky performance status 60 . Adequate organ bone marrow function define hematological serum chemistry limit . At least 18 year old . Both men woman must practice adequate contraception . Informed consent . Progressed temozolomide . Evidence acute intracranial intratumoral hemorrhage &gt; Grade 1 . Not recover toxic effect prior therapy . Pregnant breast feeding . History diabetes mellitus . Uncontrolled intercurrent illness . Congestive heart failure , unstable angina , myocardial infarction within 3 month enter study . HIV positive . Diagnosis another malignancy may exclude subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cytokine-Induced Killer Cells</keyword>
	<keyword>Milignant Gliomas</keyword>
	<keyword>Temozolomide</keyword>
</DOC>